î
î
NovaBay Pharmaceuticals Inc
NBY0.614USD
+0.021+3.45%
āđāļ§āļĨāļēāļāļģāļāļēāļĢāļāļĨāļēāļÂ ïžETïžāļĢāļēāļāļēāļĨāđāļēāļāđāļē 15 āļāļēāļāļĩ
3.57MāļĄāļđāļĨāļāđāļēāļāļĨāļēāļ
1.34P/E TTM
î
āļĢāļēāļĒāļĨāļ°āđāļāļĩāļĒāļāđāļāļīāđāļĄāđāļāļīāļĄāļāļāļ NovaBay Pharmaceuticals Inc āļāļĢāļīāļĐāļąāļ
NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.
āļāđāļāļĄāļđāļĨāļāļĢāļīāļĐāļąāļî
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļNBY
āļāļ·āđāļāļāļĢāļīāļĐāļąāļNovaBay Pharmaceuticals Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 26, 2007
āļāļĩāļāļĩāđāļMr. Justin M. Hall, Esq.
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ14
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļOct 26
āļāļĩāđāļāļĒāļđāđ2000 Powell St Ste 1150
āđāļĄāļ·āļāļEMERYVILLE
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNYSE American Consolidated
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ94608-1804
āđāļāļĢāļĻāļąāļāļāđ15108998800
āđāļ§āđāļāđāļāļāđhttps://novabay.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļNBY
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 26, 2007
āļāļĩāļāļĩāđāļMr. Justin M. Hall, Esq.
āļāļđāđāļāļĢāļīāļŦāļēāļĢāļāļĢāļīāļĐāļąāļî
āļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Mr. Justin M. Hall, Esq.
Mr. Justin M. Hall, Esq.
Chief Executive Officer, Chief Compliance Officer, General Counsel, Director
Chief Executive Officer, Chief Compliance Officer, General Counsel, Director
580.00
-0.34%
Mr. Mijia (Bob) Wu
Mr. Mijia (Bob) Wu
Director
Director
122.00
--
Ms. Swan Sit
Ms. Swan Sit
Independent Director
Independent Director
92.00
--
Mr. Yongxiang (Sean) Zheng
Mr. Yongxiang (Sean) Zheng
Director
Director
50.00
--
Ms. Julie Garlikov
Ms. Julie Garlikov
Independent Director
Independent Director
50.00
--
Mr. Tommy Law
Mr. Tommy Law
Interim Chief Financial Officer, Treasurer
Interim Chief Financial Officer, Treasurer
26.00
--
Mr. Paul E. Freiman, Ph.D.
Mr. Paul E. Freiman, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Yenyou (Jeff) Zheng, Ph.D.
Dr. Yenyou (Jeff) Zheng, Ph.D.
Independent Director
Independent Director
--
--
Capt. Jody Cain
Capt. Jody Cain
IR Contact Officer
IR Contact Officer
--
--
āļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Mr. Justin M. Hall, Esq.
Mr. Justin M. Hall, Esq.
Chief Executive Officer, Chief Compliance Officer, General Counsel, Director
Chief Executive Officer, Chief Compliance Officer, General Counsel, Director
580.00
-0.34%
Mr. Mijia (Bob) Wu
Mr. Mijia (Bob) Wu
Director
Director
122.00
--
Ms. Swan Sit
Ms. Swan Sit
Independent Director
Independent Director
92.00
--
Mr. Yongxiang (Sean) Zheng
Mr. Yongxiang (Sean) Zheng
Director
Director
50.00
--
Ms. Julie Garlikov
Ms. Julie Garlikov
Independent Director
Independent Director
50.00
--
Mr. Tommy Law
Mr. Tommy Law
Interim Chief Financial Officer, Treasurer
Interim Chief Financial Officer, Treasurer
26.00
--
āļŠāļąāļāļŠāđāļ§āļāļāļāļāļĢāļēāļĒāđāļāđ
āļŠāļāļļāļĨāđāļāļīāļ: USDāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļēāļāļīāļāļĒāđāļāļĩāđ 6 āļ.āļ.
āļŠāļāļļāļĨāđāļāļīāļ: USDāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļēāļāļīāļāļĒāđāļāļĩāđ 6 āļ.āļ.
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
āļāļēāļĄāļāļļāļĢāļāļīāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
Avenova
8.67M
88.67%
Other products
1.07M
10.98%
Other revenue, net
34.00K
0.35%
NeutroPhase
0.00
0.00%
āļāļēāļĄāļ āļđāļĄāļīāļ āļēāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
United States
9.78M
100.00%
āļāļēāļĄāļāļļāļĢāļāļīāļ
āļāļēāļĄāļ āļđāļĄāļīāļ āļēāļ
āļāļēāļĄāļāļļāļĢāļāļīāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
Avenova
8.67M
88.67%
Other products
1.07M
10.98%
Other revenue, net
34.00K
0.35%
NeutroPhase
0.00
0.00%
āļŠāļāļīāļāļīāļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļēāļāļīāļāļĒāđāļāļĩāđ 27 āļ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļēāļāļīāļāļĒāđāļāļĩāđ 27 āļ.āļ.
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļĢāļ°āđāļ āļāļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
Poplar Point Capital Management LLC
17.54%
Sabby Management, LLC
3.75%
C2C Wealth Management, LLC
1.68%
Geode Capital Management, L.L.C.
0.60%
XTX Markets LLC
0.34%
Other
76.08%
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
Poplar Point Capital Management LLC
17.54%
Sabby Management, LLC
3.75%
C2C Wealth Management, LLC
1.68%
Geode Capital Management, L.L.C.
0.60%
XTX Markets LLC
0.34%
Other
76.08%
āļāļĢāļ°āđāļ āļāļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
Hedge Fund
17.94%
Investment Advisor/Hedge Fund
4.35%
Investment Advisor
1.89%
Venture Capital
0.34%
Individual Investor
0.02%
Other
75.46%
āļāļēāļĢāļāļ·āļāļŦāļļāđāļāļāļāļāļŠāļāļēāļāļąāļî
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļēāļĢāļāļĩāđ 1 āļ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļēāļĢāļāļĩāđ 1 āļ.āļ.
āļāđāļ§āļāđāļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļāļēāļ
āļāļģāļāļ§āļāļŠāļāļēāļāļąāļ
āļŦāļļāđāļāļāļĩāđāļāļ·āļāļāļĢāļāļ
āļŠāļąāļāļŠāđāļ§āļ
āđāļāļĨāļĩāđāļĒāļ
2025Q2
43
1.43M
24.54%
+213.78K
2025Q1
42
1.34M
22.96%
+376.59K
2024Q4
40
546.91K
11.19%
+390.20K
2024Q3
42
126.44K
2.60%
+79.02K
2024Q2
44
12.01K
0.89%
-33.08K
2024Q1
44
12.73K
1.48%
-22.10K
2023Q4
45
34.29K
18.48%
+25.73K
2023Q3
47
15.18K
15.11%
-444.00
2023Q2
47
9.53K
10.53%
-5.30K
2023Q1
51
13.02K
22.50%
-2.13K
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļīāļāļāļĢāļĢāļĄāļāļđāđāļāļ·āļāļŦāļļāđāļî
āļāļ·āđāļ
āļŦāļļāđāļāļāļĩāđāļāļ·āļāļāļĢāļāļ
āļŠāļąāļāļŠāđāļ§āļ
āđāļāļĨāļĩāđāļĒāļ
āđāļāļĨāļĩāđāļĒāļ%
āļ§āļąāļāļāļĩāđ
Poplar Point Capital Management LLC
1.02M
17.54%
+19.91K
+1.99%
Jun 03, 2025
Sabby Management, LLC
218.04K
3.75%
+218.04K
--
Mar 31, 2025
C2C Wealth Management, LLC
55.00K
0.95%
+4.10K
+8.05%
Mar 31, 2025
Geode Capital Management, L.L.C.
35.00K
0.6%
+1.97K
+5.95%
Mar 31, 2025
XTX Markets LLC
19.85K
0.34%
+3.71K
+22.98%
Mar 31, 2025
Two Sigma Investments, LP
17.47K
0.3%
-13.94K
-44.37%
Mar 31, 2025
Susquehanna International Group, LLP
10.56K
0.18%
+10.56K
--
Mar 31, 2025
Tower Research Capital LLC
5.46K
0.09%
+6.00
+0.11%
Mar 31, 2025
UBS Financial Services, Inc.
749.00
0.01%
+749.00
--
Mar 31, 2025
Hall (Justin M)
580.00
0.01%
-2.00
-0.34%
Mar 18, 2025
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
ETF āļāļĩāđāđāļāļĩāđāļĒāļ§āļāđāļāļî
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāđāļŠāļēāļĢāđāļāļĩāđ 2 āļŠ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāđāļŠāļēāļĢāđāļāļĩāđ 2 āļŠ.āļ.
āļāļ·āđāļ
āļŠāļąāļāļŠāđāļ§āļ
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
āļŠāļąāļāļŠāđāļ§āļ0%
āđāļāļīāļāļāļąāļāļāļĨî
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē
āļ§āļąāļāļāļĩāđ
āđāļāļīāļāļāļąāļāļāļĨ
āļ§āļąāļāļāļĩāđāļāļąāļāļāļķāļ
āļ§āļąāļāļāļĩāđāļāļģāļĢāļ°āđāļāļīāļ
āļ§āļąāļāļāļĩāđāđāļĄāđāđāļāđāļĢāļąāļāļŠāļīāļāļāļīāļāļąāļāļāļĨ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
āļāļēāļĢāđāļāđāļāļŦāļļāđāļî
āļ§āļąāļāļāļĩāđ
āļāļĢāļ°āđāļ āļ
āļāļąāļāļĢāļēāļŠāđāļ§āļ
Apr 18, 2024
Merger
35<1
Apr 18, 2024
Merger
35<1
Apr 18, 2024
Merger
35<1
Apr 18, 2024
Merger
35<1
Nov 14, 2022
Merger
35<1
Nov 14, 2022
Merger
35<1
āļ§āļąāļāļāļĩāđ
āļāļĢāļ°āđāļ āļ
āļāļąāļāļĢāļēāļŠāđāļ§āļ
Apr 18, 2024
Merger
35<1
Apr 18, 2024
Merger
35<1
Apr 18, 2024
Merger
35<1
Apr 18, 2024
Merger
35<1
Nov 14, 2022
Merger
35<1
Nov 14, 2022
Merger
35<1
Nov 14, 2022
Merger
35<1
Nov 14, 2022
Merger
35<1
